CTOs on the Move

PeerBridge Health

www.peerbridgehealth.com

 
Peerbridge Health, Inc. is a mobile health IT company seeking to bring independence and precision with remote monitoring capabilities for medical, wellness and performance-based needs including the monitoring of vital signs, with thoughtful design and a seamless user experience.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

PeerBridge Health raised $11M on 11/19/2019

Similar Companies

Lila Natural Cosmetics

Lila Natural Cosmetics is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nueterra

Nueterra Capital is a private equity investment and advisory firm with an exclusive focus on healthcare. Leveraging a deep understanding of key industry drivers, Nueterra Capital invests in entrepreneurs with innovative minds, while providing professional expertise and back office resources to improve their bottom line performance and drive growth. Nueterra Capital has invested in hundreds of new ventures and continuously delivers the resources and strategic direction that allow our partners to advance and improve every aspect of healthcare.

Medical Knowledge Group

Medical Knowledge Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Battle Creek Health System

Battle Creek Health System (BCHS) is a multi-campus health care provider serving approximately 200,000 people in south central Michigan. BCHS was formed through the merger of Battle Creek's two acute care hospitals-Leila Y. Post Montgomery Hospital and

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.